Sponsor
MERCK SHARP & DOHME CORP
Principal Investigator
CECILIA CARMEN CARPIO SEGURA
Service
Hematology
Cohort for hematological patients available
Study details
Tumor type: HODGKIN LYMPHOMA (HL)
Stage: Relapsed/Refractory
Main Investigational Agent : Immunotherapy
Phase: III
Randomization: Randomized
Molecular details
Biomarker: Not applicable
Biomarker criteria: Not applicable
Prescreening: Not applicable
Additional study population requirements: Not applicable
Drug details
Arm A: Coformulated Favezelimab/Pembrolizumab
Arm B: Chemotherapy (Bendamustine or Gemcitabine)
